Among men with locally advanced prostate cancer who stopped goserelin early, more than 5 years of goserelin was significantly associated with better overall survival than shorter durations, including after adjustment.
In plain wordsIn men with prostate cancer, goserelin for more than 5 years was linked to better survival than shorter goserelin durations.
- Peptide
- Goserelin
- Outcome
- IncreaseOverall survival
- Study
n = 189
- Comparator
- Other goserelin duration groups (<= 1 year; > 1 and <= 5 years)
- Outcome group
- Mortality · Cancer
- Studied dose
- Dose not stated · More than 5 yearsAs given in this study (human).
Source sentences
The HTD more than 5 years group is significantly associated with an improved survival and DFS and fewer DMs than other HTD groups.
5 context sentences(design, population, supporting numbers)
After adjustment for age, radical prostatectomy, nodal status, Gleason score, and stage variables, the HTD more than 5 years group remains significantly associated with better OS and DFS than other HTD groups.
We correlated duration of adjuvant hormonal therapy and outcomes among patients who prematurely discontinued hormonal therapy.
The protocol mandated pelvic radiotherapy followed by goserelin given indefinitely or until disease progression.
There were 189 analyzable patients.
Patients were divided in groups based on the tertile of hormonal therapy duration (HTD) as follows: < or = 1 year, more than 1 year and < or = 5 years, and more than 5 years.